Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
Lung Cancer Update
00:00
Integrating HER2-Specific Therapy in NSCLC Treatment
This chapter explores the integration of TDXD specifically for treating non-small cell lung cancer (NSCLC) and its approval for HER2 mutants. It highlights response rates and the implications of HER2 overexpression on patient demographics and treatment strategies.
Transcript
Play full episode
